Cosciens Biopharma (TSX:CSCI) Shiller PE Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CSCI Cosciens Biopharma Inc TSX:CSCI
68 GF Score
Price C$7.60
GF Value C$9.75
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cosciens Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cosciens Biopharma  (TSX:CSCI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cosciens Biopharma Shiller PE Ratio Related Terms


Cosciens Biopharma Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Shiller PE Ratio Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.18 18.75 8.34 123.98 0.00

Cosciens Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSX:CSCI vs VRTX, REGN, MRNA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Shiller PE Ratio falls into.


TSX:CSCI
68GF Score
Cosciens Biopharma Inc TSX:CSCI
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cosciens Biopharma's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Cosciens Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.267/133.5265*133.5265
=-0.267

Current CPI (Jun. 2026) = 133.5265.

Cosciens Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 1.267 101.765 1.662
201612 -0.141 101.449 -0.186
201703 0.030 102.634 0.039
201706 0.627 103.029 0.813
201709 0.487 103.345 0.629
201712 -2.599 103.345 -3.358
201803 -0.496 105.004 -0.631
201806 -0.277 105.557 -0.350
201809 -0.502 105.636 -0.635
201812 0.803 105.399 1.017
201903 -1.273 106.979 -1.589
201906 -1.287 107.690 -1.596
201909 -0.170 107.611 -0.211
201912 1.248 107.769 1.546
202003 1.251 107.927 1.548
202006 1.261 108.401 1.553
202009 0.306 108.164 0.378
202012 -1.095 108.559 -1.347
202103 1.266 110.298 1.533
202106 1.253 111.720 1.498
202109 1.263 112.905 1.494
202112 1.278 113.774 1.500
202203 2.578 117.646 2.926
202206 2.526 120.806 2.792
202209 1.240 120.648 1.372
202212 0.004 120.964 0.004
202303 -0.633 122.702 -0.689
202306 -1.873 124.203 -2.014
202309 -1.705 125.230 -1.818
202312 -3.421 125.072 -3.652
202403 -3.086 126.258 -3.264
202406 -2.631 127.522 -2.755
202409 -7.518 127.285 -7.887
202412 -10.044 127.364 -10.530
202503 -4.996 129.181 -5.164
202506 -3.513 129.892 -3.611
202509 -2.366 130.287 -2.425
202512 -2.814 130.366 -2.882
202603 11.936 132.262 12.050
202606 -0.267 133.527 -0.267

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cosciens Biopharma (TSX:CSCI) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of C$7.60 is trading 22.1% below its estimated GF Value™ of C$9.75. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for TSX:CSCI:

  • Shiller PE Ratio:
  • GF Value™: C$9.75 vs. price of C$7.60 (22.1% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the TSX:CSCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cosciens Biopharma Business Description

Other Exchanges CSCIF:USAET8:Germany
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
68GF Score

Get the complete analysis for TSX:CSCI

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$7.60
Price
C$9.75
GF Value